Bristol-Myers Squibb (BMY)
49.75
-0.94 (-1.85%)
NYSE · Last Trade: Jun 14th, 3:14 PM EDT
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Via Benzinga · June 12, 2025
Via The Motley Fool · June 8, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.
Via Chartmill · June 6, 2025

Via The Motley Fool · June 5, 2025

A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · June 5, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
Via Benzinga · June 2, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.
Via Stocktwits · June 2, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high dividend yield, strong profitability, and an undervalued stock price, making it a candidate for value investors.
Via Chartmill · May 31, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · May 29, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via StockStory · May 22, 2025
Via The Motley Fool · May 21, 2025
Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.
Via Benzinga · May 16, 2025
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Via Benzinga · May 16, 2025
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers a high 5.29% dividend yield with strong growth and profitability, making it a solid pick for income investors.
Via Chartmill · May 16, 2025
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Via Chartmill · May 15, 2025
Via The Motley Fool · May 15, 2025
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.
Via Chartmill · May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
Via Benzinga · May 14, 2025
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.
Via Benzinga · May 13, 2025
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.
Via Investor's Business Daily · May 13, 2025
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.
Via Chartmill · May 13, 2025